Therefore, AML with somatic RUNX1 variants is considered a biologically distinct AML subtype associated with poor outcomes in the 2016 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia [24]. The gene discussed is RUNX1; the disease is acute leukemia.